A detailed history of Credit Suisse Ag transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 37,459 shares of RAPT stock, worth $42,703. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,459
Previous 37,425 0.09%
Holding current value
$42,703
Previous $930,000 63.87%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$6.87 - $26.45 $233 - $899
34 Added 0.09%
37,459 $336,000
Q4 2023

Feb 08, 2024

BUY
$11.28 - $25.46 $40,472 - $91,350
3,588 Added 10.6%
37,425 $930,000
Q3 2023

Nov 13, 2023

SELL
$16.34 - $24.66 $84,657 - $127,763
-5,181 Reduced 13.28%
33,837 $562,000
Q2 2023

Aug 11, 2023

BUY
$16.06 - $21.61 $12,382 - $16,661
771 Added 2.02%
39,018 $729,000
Q1 2023

May 10, 2023

BUY
$17.19 - $30.8 $81,961 - $146,854
4,768 Added 14.24%
38,247 $701,000
Q4 2022

Feb 13, 2023

BUY
$16.28 - $24.6 $230,850 - $348,828
14,180 Added 73.48%
33,479 $662,000
Q3 2022

Nov 10, 2022

BUY
$17.96 - $30.46 $88,919 - $150,807
4,951 Added 34.51%
19,299 $463,000
Q2 2022

Aug 12, 2022

BUY
$10.26 - $23.59 $16,539 - $38,027
1,612 Added 12.66%
14,348 $261,000
Q1 2022

May 16, 2022

BUY
$17.02 - $40.22 $14,739 - $34,830
866 Added 7.3%
12,736 $280,000
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $11,475 - $15,365
389 Added 3.39%
11,870 $436,000
Q3 2021

Nov 12, 2021

BUY
$29.86 - $39.47 $63,124 - $83,439
2,114 Added 22.57%
11,481 $357,000
Q2 2021

Aug 16, 2021

SELL
$17.99 - $40.02 $19,609 - $43,621
-1,090 Reduced 10.42%
9,367 $297,000
Q1 2021

May 14, 2021

BUY
$16.0 - $24.46 $1,056 - $1,614
66 Added 0.64%
10,457 $231,000
Q4 2020

Feb 12, 2021

BUY
$15.89 - $40.87 $165,112 - $424,680
10,391 New
10,391 $205,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $33.8M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.